NTRA insider trading

About Natera, Inc.

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Company website: www.natera.com

NTRA insider activity at a glance

Latest NTRA Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

13F funds holding NTRA

Frequently asked

How many insider trades does FilingIQ track for NTRA?

FilingIQ tracks 2,972 Form 4 insider transactions for NTRA (Natera, Inc.), covering filings from Nov 11, 2010 onwards. 142 of those were filed in the last 90 days.

Are NTRA insiders net buyers or net sellers?

Across the full Form 4 history for NTRA, 15 transactions (1%) were open-market purchases and 1,601 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NTRA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NTRA in?

Natera, Inc. (NTRA) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $29.41B.